Pharmacokinetics of Pamidronate in Patients With Bone Metastases by Leyvraz, S. et al.
molecules that could regulate tubulin
assembly and function in cells. It is
important to elucidate the conformation
and structure of these binding sites to
comprehend the cellular control mecha-
nisms for microtubules. In addition, such
information may prove essential for
understanding the chemotherapeutic
properties of taxol.
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Pharmacokinetics of
Pamidronate in Patients With
Bone Metastases
S. Leyvraz,* U. Hess, G. Flesch,
J. Bauer, S. Hauffe, J. M. Ford,
P. Burckhardt
Background: Pamidronate is a second-
generation bisphosphonate used in the
treatment of tumor-induced hyper-
calcemia and in the management of
bone metastases from breast cancer,
myeloma, or prostate cancer. The
pharmacokinetics of pamidronate is
unknown in cancer patients. Purpose:
To determine the influence of the rate
of administration and of bone metabo-
lism, we studied the pharmacokinetics
of pamidronate at three different infu-
sion rates in 37 patients with bone
metastases. Methods: Three groups of
11-14 patients were given 60 mg pam-
idronate as an intravenous infusion
over a period of 1, 4, or 24 hours.
Urine samples were collected in the
three groups of patients. Plasma sam-
ples were obtained only in the 1-hour
infusion group. The assay of pamidro-
nate in plasma and urine was per-
formed by high-performance liquid
chromatography with fluorescence
detection after the derivatization of
pamidronate with fluorescamine.
Results: The body retention (BR) at
0-24 hours of pamidronate represented
60%-70% of the administered dose
and was not significantly modified by
the infusion rate. In particular, the
BR at 0-24 hours was not reduced at
the fastest infusion rate. Among
patients, a threefold variability in BR
at 0-24 hours occurred, which was
related directly to the number of bone
metastases and, to some extent, to
creatinine clearance. At 60 mg/hour,
the plasma kinetics followed a multiex-
ponential course characterized by a
short distribution phase. The mean (±
SD) half-life of the distribution phase
was 0.8 hour (±0.3), the mean (±SD)
of the area under the curve for drug
concentration in plasma x time at
0-24 hours was 22.0 ± 8.8 (xmol/L x
hours, and the mean (±SD) of the
maximum plasma concentration was
9.7 (xmol/L (±3.2) . Pharmacokinetie
variables remained unchanged after
repeated infusions applied to four
patients. Clinically, the three infusion
rates were equally well tolerated with-
out significant toxicity. Conclusions:
The 1-hour infusion rate could be pro-
posed as kinetically appropriate for
the administration of pamidronate to
patients with metastatic bone diseases.
[J Natl Cancer Inst 84:788-792, 1992]
Bisphosphonates are structural ana-
logues of pyrophosphate, a natural reg-
ulator of bone mineral precipitation and
dissolution. Pamidronate is a second-
generation bisphosphonate that strongly
inhibits bone resorption without interfer-
ing with bone mineralization (7,2). Its
activity, measured by inhibition of bone
resorption, is more potent when com-
pared with the activity of etidronate and
clodronate, probably because of a direct
action on osteoclast precursors (1-4).
Pamidronate has been used widely in
benign clinical conditions such as
Paget's disease (5) and osteoporosis (6).
In malignancy, it has been administered
to treat tumor-induced hypercalcemia
(7-9) and to reduce morbidity caused by
bone metastases (10,11). The intra-
venous route of administration is gener-
ally preferred for the treatment of
malignant hypercalcemia or bone meta-
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stases, because of poor absorption by the
gut (12) and gastric irritation caused by
oral administration. The optimal sched-
ule and infusion rate have not yet been
defined, however, and might be clarified
by pharmacokinetic information.
The pharmacokinetic properties of
bisphosphonates have been determined in
laboratory animals {13,14) in which half
of the dose was accumulated in the skel-
eton and half excreted unchanged in the
urine. Accumulation of bisphosphonates
in the reticuloendothelial system of ani-
mals varies between species (15) and
between individual bisphosphonates
(16), suggesting different distribution
kinetics—factors that mandate cautious
interpretation when extrapolating data
from animals to humans.
Pamidronate pharmacokinetics were
studied in rats following oral and intra-
venous administration of l4C-labeled
compound (17). Bone accumulation was
constant at 25%-35% of dose. The up-
take of labeled pamidronate by the
reticuloendothelial system was, however,
dose dependent, with less than 3% in the
liver at 0.01 mg/kg and 30% in the liver
at 10 mg/kg. Because the liver is an
important storage compartment with a
short half-life (ti/2) of retention, further
increase of bone accumulation occurred
with time. Release of pamidronate from
the skeleton was extremely slow with an
estimated tm of at least 300 days.
In humans, pharmacokinetic data on
bisphosphonates are limited. In healthy
subjects, means of 73% and 81% of the
administered dose of clodronate were
recovered unchanged in the urine within
24-48 hours, with no difference between
the three doses tested (18,19). In six
patients with metastatic breast cancer,
total urinary excretion was similar at
75% (20). However, in patients with
Paget's disease, mean urine excretion
was lower at 58%. Because clodronate
was administered as a slow infusion over
a 5-day period, it was concluded that
slow infusion increases accumulation in
the body and decreases urine excretion
(21). It is not known by how much the
pharmacokinetics of bisphosphonates
could be affected by the rate of admin-
istration or by bone metabolism.
In initial clinical studies with pami-
dronate, multidose regimens have been
used for a period of 6-9 days, but,
recently, single-day infusions have been
shown to be equally effective and are
currently recommended (7). We report
the pharmacokinetic study of pami-
dronate given to cancer patients with
bone metastases. Pamidronate was
administered as a single infusion, at con-
stant dose, but at three different infusion
rates, to test the influence of infusion
rate on pharmacokinetic variables.
Subjects and Methods
Study Subjects
The study was conducted at the Centre
Pluridisciplinaire d'Oncologie, Univer-
sity Hospital, Lausanne, and at the
Kantonsspital, St. Gallen, Switzerland.
It was approved by the ethical committee
of both institutions. Informed consent
was obtained from every patient. Entry
criteria included an age limit greater than
or equal to 18 years, a histological diag-
nosis of cancer with radiological evi-
dence of bone metastases, serum cre-
atinine level less than 150 (xmol/L or
bilirubin level less than 25 (Jimol/L, and
normal levels of liver enzymes. Except
for one patient with a serum calcium
level at 2.91 mmol/L, the serum calcium
level was not above 2.75 mmol/L. The
patients were not treated previously with
bisphosphonates. No new medications
and no chemotherapy were started for at
least 72 hours prior to entry or at any
time during the study. Patients on hor-
mone therapy were eligible, provided
they did not have a change in treatment
schedule for at least 2 weeks. A total of
37 patients were enrolled in the study;
their characteristics are summarized in
Table 1.
Treatments
The study was performed in two
phases over a 15-month period. During
the first phase, 23 patients were ran-
domly assigned to receive 60 mg pam-
idronate, diluted in 500 mL of 0.9%
saline, as an intravenous infusion over a
period of 4 or 24 hours. To ensure ade-
quate urine flow, a total of 2 L of intra-
venous fluid was given during the day of
pamidronate administration and the fol-
lowing day. Blood samples were not
drawn during this phase of the study.
When analysis disclosed that the amount
of drug excreted in urine was similar at
both infusion rates, we started the second
phase of the study.
During the second phase, an additional
group of 14 patients was given 60 mg
pamidronate, diluted in 250 mL of 0.9%
saline, over a period of an hour without
hydration. Blood and urine samples were
collected in this group of patients.
Among this group of patients, four
were selected in whom the 1-hour infu-
sion was repeated at 4- to 5-week inter-
vals at a maximum of four infusions.
Urine Collection and Blood Sampling
During the first part of the study, urine
collections were performed at 4-hour
intervals for 12 hours (three collections)
and then at 12-hour intervals for a further
36 hours (three collections). During the
second part of the study, collection of
blank samples and two collections of
urine were performed from 0 to 4 hours
and from 4 to 24 hours.
Table 1. Patient characteristics
No. of patients
Male/female
Mean age, y (range)
Mean height, cm (range)
Mean weight, kg (range)
Median creatinine clearance, mL/min (range)
No. of breast carcinomas
No. of prostatic carcinomas
No. of bronchial carcinomas
No. of hypernephromas
No. of bone metastases*
<5
5-15
>15
Pamidronate infusion
60mg/4 h
12
2/10
67 (56-80)
162 (135-175)
62 (34-85)
65 (37-98)
10
1
1
—
3
7
2
60 mg/24 h
11
0/11
63 (28-78)
157(148-165)
60(52-71)
66 (48-102)
11
—
—
—
2
7
2
rates
60 mg/ 1 h
14
3/11
62 (42-73)
162(139-178)
65 (52-75)
68 (35-110)
11
2
—
1
1
9
4
•Evaluated on standard x rays.
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Blood samples were obtained only
during the second part of the study,
before and then every 15 minutes for 2
hours after the start of the infusion and
then at 2.5, 3, 5, and 24 hours.
Assay of Pamidronate in Urine and
Plasma
The assay of pamidronate in plasma
and urine was performed by high-
performance liquid chromatography with
fluorescence detection, after derivatiza-
tion of pamidronate with fluorescamine
(22,23). The limits of quantitation were
1.4 (jimol/L in plasma and 1.8 jjimol/L in
urine.
Clinical Assessment
In the first part of the study, serum
calcium, phosphate, creatinine, and
creatinine clearance levels were assessed
before treatment.
Because of concerns about the pos-
sibility of increased toxicity of the more
rapid infusion rate used during the sec-
ond part of the study, the following
parameters were measured in serum
before infusion and at 24 and 48 hours
after infusion: urea, creatinine, calcium,
phosphate, albumin, bilirubin, alkaline
phosphatase, and transaminases. In addi-
tion, the following parameters were
measured in urine: calcium, phosphate,
creatinine, sodium, protein, hydroxy-
proline, and lysozyme. Routine urinal-
yses were done for the presence of blood
and protein.
In all patients, the number of bone
metastases was evaluated on standard
x rays and reported in three groups—
those with fewer than five metastases,
those with between five and 15 meta-
stases, and those with more than 15 met-
astases. In seven patients, a more
accurate determination of the number of
bone metastases was obtained by bone
scan. Clinical examinations for toxicity
were performed daily during the infusion
period and then 2 to 4 weeks later.
Pharmacokinetic Calculations
Noncompartmental techniques were
used in the pharmacokinetic analysis
(24). The total urinary excretion (TUE)
at 0-24 hours was the total amount of
pamidronate excreted in urine over 24
hours. The body retention (BR) at 0-24
hours was estimated as follows: BR (%
of dose) = dose (100%) - TUE (% of
dose); fecal excretion was, in all proba-
bility, negligible as known from animal
experiments (17).
The area under the curve (AUC) for
drug concentration in plasma X time at
0-24 hours, expressed as (u,mol/L) x
hours, was determined by the linear tra-
pezoidal rule from 0 to 24 hours. Cmax
((i-mol/L) was the maximal plasma con-
centration, and Tmax (hour) was the time
at which Cmax was reached. The apparent
plasma distribution half-life (tl/2 in
hours) of pamidronate was calculated
from the slope of the linear least-squares
regression line through the concentra-
tion-time points in the time interval from
1 to about 2 hours. The total plasma
clearance (CL, [L/hour]) was calculated
as the dose/AUC (0 - <*>), taking AUC
(0-24 hours) as AUC (0 - oo) because all
24-hour plasma concentrations were
below the limit of detection and taken as
zero. The renal clearance (CLr [L/hour])
was calculated as the TUE (0-24 hour)/
AUC (0-24 hour). The nonrenal clear-
ance (CLnr [L/hour]) was CL, - CLr.
No statistical comparison of the treat-
ments was performed. This study being
the first pharmacokinetic trial with pami-
dronate disodium, no information on the
intersubject variability was available.
The results of this trial showed a high
interpatient variability in the urinary
excretion, and, therefore, the number of
patients included in each group of the
study was too low to perform meaningful
statistical tests with sufficient power.
Results
Pharmacokinetics in Urine
The TUE over 24 hours of each
patient and the mean (±SD) values are
shown graphically in Fig. 1, according to
the three different infusion rates. The
mean TUE (0-24 hours) (±SD) was not
significantly different and was measured
at 31% ± 15.2%, 34.9% ± 13.9%, and
41.0% ± 15.4% of the 60 mg of pami-
dronate administered over periods of 1
hour, 4 hours, and 24 hours, respec-
tively. Considerable between-patient
variability was noted.
To explain the wide disparity of TUE
(0-24 hours) among patients, TUE was
correlated with creatinine clearance and
with tumor bone involvement. A weak
relationship was found between cre-
atinine clearance and TUE (0-24 hours)
by linear least-squares regression anal-
ysis (r = 0.42), but a stronger associa-
tion was demonstrated between the
number of bone metastases and BR (0-24
hours). The mean (±SD) of the BR
(0-24 hours) values in patients with
fewer than five bone metastases was
50.6% ± 11.8% and increased with
increasing number of bone metastases to
76.4% ± 12.0% in patients with more
20 30
Time [h]
40
70
60
50
|60 mg in 4 h
20 30
Time [h]
20 30
Time [h]
Fig. 1. Total unnary excretion [TUE (0-24 hours)] of each patient after an infusion of 60 mg of pamidronate disodium given over 24-, 4-, and 1 -hour periods at a
constant infusion rate. Mean values are presented as dash lines.
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than 15 metastases (Fig. 2). These find-
ings were confirmed in the subgroup of
seven patients, where an accurate count
of bone involvement could be made by
bone scintigraphy and where the coeffi-
cient of correlation was 0.82 (linear
least-squares regression). No correlation
was found between serum and urine
parameters such as calcium, phosphate,
alkaline phosphatase, hydroxyproline,
and TUE (0-24 hours).
Pharmacokinetics in Plasma
After the 1-hour infusion of 60 mg of
pamidronate disodium, the mean (±SD)
of the AUC for drug concentration in
plasma x time at 0-24 hours was 22.0
± 8 . 8 (itnol/L X hours; the mean Cmax
(±SD) was 9.7 (xmol/L ± 3.2 in 14
patients. The median value of Tmax was
0.8 hour. The mean (±SD) plasma con-
centration times profile is shown in Fig.
3. The decline of pamidronate concentra-
tions in plasma followed a multiexponen-
tial course. The distribution of pami-
dronate was rapid with a mean (±SD)
apparent tV2 of 0.8 hour (±0.3). Plasma
concentrations of pamidronate were near
the limit of quantitation in most patients
at 3 hours and below the limit at 5 and
24 hours. Therefore, no terminal tm
could be estimated for the slow release
of pamidronate from bone.
Two hours after the start of the infu-
sion, a slight increase in plasma con-
centration occurred in the majority of
patients, possibly corresponding to a
release of pamidronate from an unknown
compartment. The mean (±SD) CL, was
10.7 L/hour (±3 .7 ) , and the mean
100-
8 0
6 0 -
4 0 -
2 0 -
o-
BR% of
N-
r11
•
<5
d o »
6
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Fig. 3. Mean plasma concentration-time profiles
(±SD) of pamidronate after an intravenous infusion
of 60 mg pamidronate disodium over a 1-hour
period (n = 14).
(±SD) CLr was 3.3 L/hour (±1.9). The
mean (±SD) CL,,, amounted to 7.5
L/hour (±3.2) and constituted about
70% of the CLt.
Infusions of pamidronate were re-
peated at 4- to 5-week intervals in four
patients. BR (0-24 hours) was practically
constant within each patient as shown in
Table 2. These results suggest that bone
compartment was not saturated after
repeated dosing.
Tolerance
Except for one patient who developed
a phlebitis at the infusion site, no local
or systemic toxic effects were observed.
In the group receiving the 1-hour infu-
sion, the renal parameters remained
within normal limits, including those in
patients with multiple infusions. One
patient, who had baseline gamma gluta-
myltransferase levels at three times nor-
mal before infusion, had an elevation in
the level of aspartate aminotransferase
from 9 U/L to 89 U/L (normal level,<33
U/L). In all remaining patients, liver
function tests did not show any signifi-
cant modification.
Discussion
The pharmacokinetics of pamidronate
were not influenced by the infusion rates
as suggested with clodronate (27). The
24-hour TUE (0-24 hours) was not sig-
nificantly modified when pamidronate
was administered at 2.5, 15, or 60 mg/
hour. The original hypothesis that the
faster the infusion, the greater the loss of
bisphosphonate in urine was not con-
firmed. On the contrary, the 24-hour
infusion rate had a TUE (0-24 hours) at
41% of the dose, compared with 31% for
the 1-hour infusion. BR (0-24 hours)
represented 60%-70% of the admin-
istered dose and was higher than with
other bisphosphonates (16-18). This
result could contribute to the increased
potency of pamidronate in vivo. The
studies with clodronate conducted in
healthy subjects demonstrated a BR
(0-24 hours) of 19%-27% (18,19) and in
metastatic breast cancer of 25% of the
dose (20). In one study, however, the
BR (0-24 hours) was 42% in patients
with active Paget's disease and in one
patient with prostatic cancer (21).
Bone metabolism and turnover might
affect bisphosphonate pharmacokinetics
(21,25). A direct correlation was sug-
gested between the degree of bone
involvement and BR (0-24 hours). Mean
Table 2. Pharmacokinetic parameters of pamidronate in plasma and urine*
Patient No. Infusion No.
AUC (0-24 h),
(xmol/L x h
TUE (0-24 hs),
% of dose Clr, L/h m, L/h
1
2
3
4
1
2
3
I
2
3
31.5
26.2
25.4
30.7
19.9
23.1
20.6
45.7
24.3
24.6
0.8
0.6
1.8
0.9
0.5
0.7
0.9
1-8
1.0
0.8
48
43
62
47
58
39
51
25
26
25
3.3
3.5
5.3
3.3
6.2
3.6
5.3
1.2
2.3
2.2
3.6
4.7
3.2
3.7
4.6
5.7
5.1
3.5
6.5
6.6
26.9
27.2
0.9
0.7
26
31
2.1
2.5
5.9
5.5
Fig. 2. Body retention [BR (0-24 hours)] according
to the number of bone metastases.
* After repeated intravenous infusions of 60 mg pamidronate disodium over 1-hour period at intervals of
4-5 weeks in patients with bone metastases.
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BR (0-24 hours) was 50% in patients
with few bone metastases and 75% in
those with numerous bone metastases.
The relationship was stronger in a subset
of patients in whom a more accurate
determination of the number of metasta-
tic sites was performed by counting
lesions on bone scan.
The influence of renal function on uri-
nary excretion of pamidronate is un-
known. In the population studied which
had either a normal or a slightly reduced
creatinine clearance, the renal function
had a weak effect on TUE (0-24 hours).
However, in a study in which patients
with osteodystrophy had a creatinine
clearance of only 5-35 mL/minute, TUE
(0-24 hours) of Tc-99m-etidronate was
11.4% of the administered dose (25).
The disparity in skeletal invasion and in
renal function could explain the almost
threefold variability in BR (0-24 hours)
among patients in our study.
The plasma pharmacokinetics of pami-
dronate at 60 mg/hour followed a multi-
exponential course and was characterized
by a short distribution phase in plasma,
followed by a rapid elimination of un-
changed drug in urine. The distribution
of pamidronate was rapid with a tm of
0.8 hour. Clodronate was also removed
promptly from the blood, with a tm
between 1.8 hours and 2.3 hours in
healthy subjects (16) and in patients with
bone disease (18,20). The total clearance
of pamidronate was 10.7 L/hour with a
CLnr clearance of 7.5 L/hour. For clodro-
nate, values varied between studies, with
a total clearance of 6.4 and 11.5 L/hour,
possibly due to different methods of
measurement, a factor which prevents
any direct comparison with our data.
Plasma concentration increased slightly 2
hours after the start of the infusion. Pam-
idronate may have been released from
the reticuloendothelial system, where it
could have accumulated temporarily. A
similar observation has been made in
animals but not previously in humans. In
mice, pamidronate accumulated in spleen
and liver in contrast to clodronate and
etidronate.
When pamidronate was infused at a
dose of 60 mg over a 1-hour period at 4-
to 5-week intervals, its pharmacokinetic
values remained unchanged. With this
schedule and dose, the bone compart-
ment was not saturated. Similar conclu-
sions were reached after five daily
infusions of clodronate, where no signifi-
cant variations were detectable between
daily infusions (20).
Clinically, the tolerance of patients for
all three infusion rates was similar, with
only minimal toxicity. In particular, no
renal toxicity was observed after the
1-hour infusion rate. Previous studies
have shown a transient increase in
plasma creatinine (26) and rare cases of
renal failure (27) after etidronate and
clodronate administration. The plasma
creatinine did not rise within 48 hours
after the infusion of pamidronate. Pro-
teinuria remained within normal range.
The minimal elevation of aspartate
aminotransferase seen in one patient had
no clinical significance and could be
related to a possible uptake of pami-
dronate into the reticuloendothelial sys-
tem. A larger number of patients,
however, should be studied for toxicity
at the fastest rate of infusion before
safety can be ensured.
On the basis of the pharmacokinetic
data combined with the clinical findings,
we conclude that BR (0-24 hours) of
pamidronate was dependent on the
amount of bone metastases and was not
influenced by the rate of infusion. Thus,
the 1-hour infusion rate can be proposed
as a kinetically relevant treatment sched-
ule for patients with malignant bone
diseases.
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